Cyclerion Therapeutics (CYCN) Expected to Announce Quarterly Earnings on Tuesday

Cyclerion Therapeutics (NASDAQ:CYCN) is expected to post its results before the market opens on Tuesday, March 3rd. Analysts expect Cyclerion Therapeutics to post earnings of ($0.38) per share for the quarter.

Cyclerion Therapeutics Trading Up 3.1%

Cyclerion Therapeutics stock opened at $1.35 on Monday. The company has a market cap of $5.31 million, a PE ratio of -1.80 and a beta of 0.94. Cyclerion Therapeutics has a 1 year low of $1.03 and a 1 year high of $3.79. The company’s 50-day moving average is $1.38 and its two-hundred day moving average is $1.83.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cyclerion Therapeutics currently has an average rating of “Sell”.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the third quarter, according to its most recent filing with the SEC. The firm purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. 75.62% of the stock is currently owned by institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.